Amgen Ventures, the venture capital arm of Amgen, invests in early to later-stage biotech, therapeutics, and health tech companies. Its strategy focuses on identifying and supporting emerging companies aligned with Amgen's therapeutic areas, including oncology, inflammation, metabolism, neuroscience, cardiovascular, bone health, nephrology, and diagnostics.
44% of their portfolio is in Healthcare. Their most common stage is series-b (44% of deals). Average disclosed round size is $110.3M (across 6 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Mindset Medical, Inc. | Series A | — | Jun 2024 |
| Mindset Medical, Inc. | Series A | — | Jun 2024 |
 Qualis Corporation | Series B | $88M | Mar 2023 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
 Science 37 | Series B | $40M | Aug 2020 |
| OOxford Nanopore Technologies Ltd. | Series C | $66M | Oct 2018 |
 Senti Biosciences | Series A | $53M | Feb 2018 |
 Aetion | Series B | — | — |
 Quantinuum | Growth | $300M | — |
Top Co-Investors
Sanofi Ventures3 shared
Grayhawk Capital2 shared
Lux Capital2 shared
RA Capital Management1 shared
Surveyor Capital1 shared
Cowen Healthcare Investments1 shared
Deep Track Capital1 shared
Logos Capital1 shared
Pivotal bioVenture Partners1 shared
Samsara BioCapital1 shared
Soleus Capital1 shared
Atlas Venture1 shared
Vertex Ventures HC1 shared
Bristol Myers Squibb1 shared
Vertex Pharmaceuticals1 shared
NEA (New Enterprise Associates)1 shared
8VC1 shared
Menlo Ventures1 shared
Pear1 shared
Allen & Company1 shared
Last updated: 8 March 2026